High rates of pathological complete response were reported with neoadjuvant datopotamab deruxtecan plus durvalumab in patients with specific subtypes of breast cancer and at high risk of recurrence
Final analysis of the KEYNOTE-811 trial reports positive findings when adding pembrolizumab to trastuzumab and chemotherapy in treatment-naïve patients
Final late-phase trial results show that the addition of pre-operative chemoradiotherapy to peri-operative chemotherapy does not improve long-term outcomes in patients
New positive findings from research in advanced or metastatic breast cancer support the use of these agents in wider patient populations
The fields of metastatic pancreatic NETs and advanced and low proliferative grade 3 disease tumours move forward
Results from early-phase studies reveal potential for a new cancer vaccine and adaptive immunotherapy
Subgroup analyses from the ADRIATIC study support previous practice-changing findings
In France, a nationwide programme aims to broaden access to the technology based on the positive results collected so far
Using treatments only where clear benefit has been demonstrated and modulating doses based on evidence are potentially effective strategies to reduce the rising costs of oncology
As rapid scientific and technological progress raises hopes of more cancers being intercepted at the earliest stages in the future, ESMO delves deeper into prevention to ensure education and guidance for medical oncologists in this moving field
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.